Consensus Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-06-03 EDT			5-day change	1st Jan Change
7.55 ^USD	-4.07%		-6.21%	-9.47%

05-23	Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting	CI
05-15	Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Elicio Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c6a59fa1fd398ac4c773252975.mYKIkxD-X7-51FPPD0XaFGe-Xwemj532F-LUkt7BaFk.6sSw32mSLIqKtgqYQSu2fD7LOl7h9cKTYZaBoLmnXwvB4PzGd6Q35pSyBg~11cca5209e8edc65af1bd1ee7e4e6328

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.55 USD

Average target price

10 USD

Spread / Average Target

+32.45%

High Price Target

10 USD

Spread / Highest target

+32.45%

Low Price Target

10 USD

Spread / Lowest Target

+32.45%

Consensus detail

Consensus revision (last 18 months)

Quarterly revenue - Rate of surprise

Company calendar